TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$13.47 USD
-0.44 (-3.16%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $13.46 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TGTX 13.47 -0.44(-3.16%)
Will TGTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TGTX
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Company News for Feb 29, 2024
TGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
Other News for TGTX
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)
TG Therapeutics call volume above normal and directionally bullish
TG Therapeutics wins VA contract for Briumvi
TG Therapeutics contact with VA 'unequivocal win,' says JPMorgan
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)